“…51 The most successful inhibitor design for BoNT/A LC, both in vitro and in vivo, has targeted this zinc-binding region and is headlined by hydroxamates, quinolinols, and recently, steroidal 4-aminoquinolines. [24][25][26][27][28][29][30][31][32][33][52][53][54][55][56] Despite their well-known liabilities, hydroxamates remain the most potent BoNT/A LC inhibitors. As such, the hydroxamate functional group was selected for our bifunctional inhibitor design.…”